Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Abstract Directory, Saturday, May 18, 2013<br />
Poster Session III, continued<br />
3:45 PM - 5:45 PM<br />
Room: Exhibit Hall C/D<br />
Cancer-Oncolytic Viruses II<br />
638<br />
Development <strong>of</strong> Dual Targeted Oncolytic Adenovirus<br />
for Human Malignant Mesothelioma<br />
Shuji Kubo, Misato Takagi-Kimura, Atsuko Tamamoto, Tomoko<br />
Hashimoto-Tamaoki, Noriyuki Kasahara, Masatoshi Tagawa.<br />
639<br />
MicroRNA-Mediated Multi-Tissue-Detargeting <strong>of</strong><br />
Oncolytic Measles Virus<br />
Marc-Andrea Bärtsch, Mathias F. Leber, Sascha Bossow,<br />
Martin Singh, Jessica Albert, Dirk Jäger, Christ<strong>of</strong> von Kalle, Guy<br />
Ungerechts.<br />
646 Abstract Withdrawn from Presentation<br />
647<br />
Iraqi Newcastle Disease Virus Virulent Strain as Cancer<br />
Antiangiogenic Agent<br />
Ahmed M. Al-Shammari, Zaid A. Al-Hili, Nahi Y. Yaseen.<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: <strong>Cell</strong><br />
<strong>Therapy</strong> / Immunotherapy / <strong>Cell</strong>ular Targets<br />
648<br />
Neural Stem <strong>Cell</strong>s Expressing a Modiied Human<br />
Carboxylesterase Potentiate Anti-Cancer Activity <strong>of</strong><br />
Irinotecan in Murine Glioma Model<br />
Karen S. Aboody, Lucy Y. Ghoda, Margarita Gutova, Megan<br />
Gilchrist, Christine Brown, Vazgen Kankaldyyan, Elizabth Garcia,<br />
Lauren H<strong>of</strong>fman, Rex A. Moats, Phil Potter, Timothy W. Synold,<br />
Michael Barish.<br />
640<br />
In Vivo Therapeutic Eficacy <strong>of</strong> Oncolytic Adenovirus<br />
Delivered by New Biodegradable Polymers through<br />
Systemic Injection<br />
Jaesung Kim, Yi Li, Sung Wan Kim, Doo Sung Lee, Chae-Ok Yun.<br />
641<br />
Eficacy <strong>of</strong> Measles Virotherapy in Osteosarcoma<br />
Evidio Domingo Musibay, Cory Allen, Ianko D. Iankov, Jayson J.<br />
Hardcastle, Evanthia Galanis.<br />
642<br />
A Cancer-Targeting Ligand Strongly Enhances Oncolytic<br />
Activity <strong>of</strong> a Conditionally Replicative Adenovirus<br />
Yuki Yamamoto, Naoko Goto, Shumpei Ohnami, Masatoshi Tagawa,<br />
Kazunori Aoki.<br />
643<br />
Cyclophosphamide Enhances Antitumor<br />
Eficacy <strong>of</strong> Oncolytic Adenovirus Expressing<br />
Uracil Phosphoribosyltransferase (UPRT) in<br />
Immunocompetent Syrian Hamsters<br />
Naoyuki Hasegawa, Masato Abei, Kazunari K. Yokoyama, Kuniaki<br />
Fukuda, Emiko Seo, Rei Kawashima, Yuri Nakano, Takeshi Yamada,<br />
Koji Nakade, Hir<strong>of</strong>umi Hamada, Yuichi Obata, Ichinosuke Hyodo.<br />
644<br />
Therapeutic Evaluation <strong>of</strong> Prostate Cancer Speciic<br />
Oncolytic Adenovirus Armed with Fusion Protein <strong>Gene</strong><br />
PSA-IZ-CD40L<br />
Yue-feng Yang, Shu-Ya Xue, Hua Wang, Feng-jun Xiao, Yue Yin,<br />
Zhuo-zhuang Lu, Qun-wei Zhang, Chu-tse Wu, Li-sheng Wang.<br />
645<br />
Bioreducible Polymer-Conjugated Oncolytic<br />
Adenovirus for Hepatoma-Speciic <strong>Therapy</strong> Via<br />
Systemic Administration<br />
Pyung-Hwan Kim, Jaesung Kim, Tae-il Kim, Hye Yeong Nam, James<br />
W. Yockman, Minjung Kim, Sung Wan Kim, Chae-Ok Yun.<br />
649<br />
Re-Directing T <strong>Cell</strong>s with Chimeric Antigen Receptors<br />
To Target CD123+ Leukemia<br />
Radhika Thokala, Kirsten Switzer, Mi Ti juan, Simon Olivares,<br />
Harjeet Singh, Helen Huls, Richard E. Champlin, Laurence J. N.<br />
Cooper.<br />
650<br />
The Speciicity <strong>of</strong> Rhesus T <strong>Cell</strong>s Can Be Redirected<br />
to CD20 Using the Sleeping Beauty Transposon/<br />
Transposase System To Express a Chimeric Antigen<br />
Receptor<br />
Simon Olivares, Colleen O’Connor, Sonny Ang, Leslie Kean, Perry<br />
Hackett, Amer Najjar, Harjeet Singh, Helen Huls, Elizabeth Shpall,<br />
Laurence Cooper.<br />
651<br />
Tumor Targeting Using CD19-Speciic CAR (Chimeric<br />
Antigen Receptor) for B-<strong>Cell</strong> Lymphoma<br />
Tomonori Tsukahara, Ken Ohmine, Ryosuke Uchibori, Hiroyuki<br />
Ido, Masashi Urabe, Hiroaki Mizukami, Akihiro Kume, Masataka<br />
Nakamura, Junichi Mineno, Kazutoh Takesako, Isabelle Riviere,<br />
Michel Sadelain, Renier Brentjens, Keiya Ozawa.<br />
652<br />
Tumor Relapse Is Associated with an Innate Immune<br />
Resistant Phenotype across Tumor and Treatment<br />
Types Which Can Be Targeted with Rational Second<br />
Line Therapies<br />
Timothy Kottke, Oliver Donnelly, Nicolas Boisgerault, Rosa<br />
Diaz, Diana Rommelfanger-Konkol, Jose Pulido, Jill Thompson,<br />
Debabrata Mukhopadhyay, Keith Knutson, Marshall Behrens,<br />
Roger Kaspar, Matt C<strong>of</strong>fey, Peter Selby, Kevin Harrington, Alan<br />
Melcher, Hardev Pandha, Richard Vile.<br />
653<br />
Chimeric Antigen Receptor T-<strong>Cell</strong> <strong>Therapy</strong> for<br />
Companion Canines with Spontaneous B-<strong>Cell</strong> Non-<br />
Hodgkin Lymphoma<br />
Colleen M. O’Connor, Simon Olivares, Sonny Ang, Richard E.<br />
Champlin, Heather M. Wilson-Robles, Laurence J. N. Cooper.<br />
Saturday, May 18, 2013<br />
<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />
135
Change language